دورية أكاديمية
أعرض في EDS

T-independent response mediated by oncolytic tanapoxvirus recombinants expressing interleukin-2 and monocyte chemoattractant protein-1 suppresses human triple negative breast tumors.

التفاصيل البيبلوغرافية
العنوان: T-independent response mediated by oncolytic tanapoxvirus recombinants expressing interleukin-2 and monocyte chemoattractant protein-1 suppresses human triple negative breast tumors.
المؤلفون: Suryawanashi YR; Laboratory of Virology, Department of Biological Sciences, Western Michigan University, Kalamazoo, MI, 49008-5410, USA., Zhang T; Laboratory of Virology, Department of Biological Sciences, Western Michigan University, Kalamazoo, MI, 49008-5410, USA., Woyczesczyk HM; Laboratory of Virology, Department of Biological Sciences, Western Michigan University, Kalamazoo, MI, 49008-5410, USA., Christie J; Laboratory of Virology, Department of Biological Sciences, Western Michigan University, Kalamazoo, MI, 49008-5410, USA.; The Biodesign Institute, Arizona State University, Tempe, AZ, USA., Byers E; Laboratory of Virology, Department of Biological Sciences, Western Michigan University, Kalamazoo, MI, 49008-5410, USA.; General Toxicology, MPI Research, Mattawan, MI, USA., Kohler S; Laboratory of Virology, Department of Biological Sciences, Western Michigan University, Kalamazoo, MI, 49008-5410, USA., Eversole R; Laboratory of Virology, Department of Biological Sciences, Western Michigan University, Kalamazoo, MI, 49008-5410, USA., Mackenzie C; Department of Pathology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK., Essani K; Laboratory of Virology, Department of Biological Sciences, Western Michigan University, Kalamazoo, MI, 49008-5410, USA. karim.essani@wmich.edu.
المصدر: Medical oncology (Northwood, London, England) [Med Oncol] 2017 Jun; Vol. 34 (6), pp. 112. Date of Electronic Publication: 2017 May 02.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 9435512 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1559-131X (Electronic) Linking ISSN: 13570560 NLM ISO Abbreviation: Med Oncol Subsets: MEDLINE
أسماء مطبوعة: Publication: 2011- : New York : Springer
Original Publication: Northwood, Middlesex, England : Science and Technology Letters, c1994-
مواضيع طبية MeSH: Chemokine CCL2/*metabolism , Immunotherapy/*methods , Interleukin-2/*metabolism , Oncolytic Viruses/*genetics , Triple Negative Breast Neoplasms/*metabolism , Yatapoxvirus/*genetics, Animals ; Aotidae ; Cell Line ; Chemokine CCL2/genetics ; Chemokine CCL2/immunology ; Humans ; Interleukin-2/genetics ; Interleukin-2/immunology ; Male ; Mice ; Mice, Nude ; Oncolytic Viruses/metabolism ; Triple Negative Breast Neoplasms/genetics ; Triple Negative Breast Neoplasms/immunology ; Xenograft Model Antitumor Assays ; Yatapoxvirus/metabolism
مستخلص: Human triple negative breast cancer (TNBC) is an aggressive disease, associated with a high rate of recurrence and metastasis. Current therapeutics for TNBC are limited, highly toxic and show inconsistent efficacy due to a high degree of intra-tumoral and inter-tumoral heterogeneity. Oncolytic viruses (OVs) are an emerging treatment option for cancers. Several OVs are currently under investigation in preclinical and clinical settings. Here, we examine the oncolytic potential of two tanapoxvirus (TPV) recombinants expressing mouse monocyte chemoattractant protein (mMCP)-1 [also known as mCCL2] and mouse interleukin (mIL)-2, in human TNBC, in vitro and in vivo. Both wild-type (wt) TPV and TPV recombinants demonstrated efficient replicability in human TNBC cells and killed cancer cell efficiently in a dose-dependent manner in vitro. TPV/∆66R/mCCL2 and TPV/∆66R/mIL-2 expressing mCCL2 and mIL-2, respectively, suppressed the growth of MDA-MB-231 tumor xenografts in nude mice significantly, as compared to the mock-injected tumors. Histological analysis of tumors showed areas of viable tumor cells, necrotic foci and immune cell accumulation in virus-treated tumors. Moreover, TPV/∆66R/mIL-2-treated tumors showed a deep infiltration of mononuclear immune cells into the tumor capsule and focal cell death in tumors. In conclusion, TPV recombinants expressing mCCL2 and mIL-2 showed a significant therapeutic effect in MDA-MB-231 tumor xenografts, in nude mice through induction of potent antitumor immune responses. Considering the oncolytic potency of armed oncolytic TPV recombinants expressing mCCL2 and mIL-2 in an experimental nude mouse model, these viruses merit further investigation as alternative treatment options for human breast cancer.
References: Semin Cancer Biol. 2004 Jun;14(3):149-54. (PMID: 15246049)
Gynecol Oncol. 1999 Nov;75(2):198-210. (PMID: 10525372)
J Biol Chem. 2012 Oct 19;287(43):36593-608. (PMID: 22927430)
Nature. 2005 Jul 28;436(7050):518-24. (PMID: 16049480)
Oncoimmunology. 2014 Jun 03;3:e29030. (PMID: 25083328)
Cancer Res. 2003 Nov 1;63(21):7451-61. (PMID: 14612545)
J Immunol. 1975 Sep;115(3):844-7. (PMID: 807647)
Immunol Cell Biol. 2017 Apr;95(4):356-363. (PMID: 28003642)
Breast Cancer Res. 2014 May 20;16(3):210. (PMID: 25928070)
Dis Model Mech. 2008 Sep-Oct;1(2-3):78-82. (PMID: 19048064)
Nature. 2013 Sep 19;501(7467):328-37. (PMID: 24048065)
Biochim Biophys Acta. 2013 Jul;1832(7):989-97. (PMID: 23246690)
Oncotarget. 2016 May 10;7(19):28697-710. (PMID: 26885690)
Int J Health Geogr. 2014 Sep 25;13:34. (PMID: 25255815)
Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3652-6. (PMID: 8170963)
F1000Prime Rep. 2015 Jan 05;7:09. (PMID: 25705392)
Can J Microbiol. 1999 Jan;45(1):92-6. (PMID: 10349725)
Cancer. 2007 Aug 15;110(4):876-84. (PMID: 17620276)
J Immunol Res. 2016;2016:4789279. (PMID: 26885534)
Virus Genes. 2017 Feb;53(1):52-62. (PMID: 27738905)
J Biol Chem. 2009 Oct 16;284(42):29087-96. (PMID: 19720836)
J Leukoc Biol. 1996 Sep;60(3):365-71. (PMID: 8830793)
Br Med J. 1971 Feb 13;1(5745):363-8. (PMID: 5541925)
N Engl J Med. 2010 Nov 11;363(20):1938-48. (PMID: 21067385)
Oncoimmunology. 2015 Dec 8;5(1):e1115641. (PMID: 26942095)
Cancer Res. 2011 Apr 1;71(7):2466-75. (PMID: 21427357)
J Geriatr Oncol. 2014 Jul;5(3):307-14. (PMID: 24821377)
Curr Opin Immunol. 2011 Oct;23(5):598-604. (PMID: 21889323)
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. (PMID: 26742998)
Med Oncol. 2017 Mar;34(3):43. (PMID: 28185165)
Oncoimmunology. 2014 Jun 01;3:e28694. (PMID: 25097804)
Cancer Res. 2007 Oct 15;67(20):10038-46. (PMID: 17942938)
Cancer Gene Ther. 2005 Apr;12(4):359-68. (PMID: 15678154)
Science. 1994 Jun 24;264(5167):1918-21. (PMID: 8009221)
Annu Rev Virol. 2014 Sep 1;1(1):119-141. (PMID: 25839047)
Nature. 1981 May 28;291(5813):335-8. (PMID: 6164929)
J Immunol. 2010 Jun 1;184(11):6114-23. (PMID: 20427772)
BBA Clin. 2015 Mar 12;3:257-75. (PMID: 26676166)
J Exp Clin Cancer Res. 2015 Feb 19;34:19. (PMID: 25887490)
فهرسة مساهمة: Keywords: Antitumor macrophages; Interleukin-2; Monocyte chemoattractant protein-1/CCL2; Oncolytic virus; Tanapoxvirus; Triple negative breast cancer
المشرفين على المادة: 0 (Chemokine CCL2)
0 (Interleukin-2)
تواريخ الأحداث: Date Created: 20170504 Date Completed: 20180111 Latest Revision: 20220801
رمز التحديث: 20221213
DOI: 10.1007/s12032-017-0973-7
PMID: 28466296
قاعدة البيانات: MEDLINE
الوصف
تدمد:1559-131X
DOI:10.1007/s12032-017-0973-7